

Historical Review

A Look Back on the History of Cerebral Revascularization for Acute Ischemic Stroke: A Neurosurgeon's Perspective

Jay Max Findlay 

Department of Surgery, University of Alberta, Edmonton, AB, Canada

ABSTRACT: This review looks back on our experience with acute middle cerebral artery embolectomies in the 1990s, frowned upon by stroke experts at the time, and no match for the newly introduced and proven treatment of acute ischemic stroke with intravenous recombinant tissue plasminogen activator (alteplase). The past several decades have seen dramatic developments in acute cerebral revascularization, the major paradigm shift being in the form of endovascular thrombectomy. Mechanical thrombectomy has moved from the operating room, where we performed it, to the interventional angiography suite armed with ever-improving clot aspiration and retrieval technologies.

RÉSUMÉ : Retour sur l'histoire de la revascularisation cérébrale dans le cas d'AVC ischémiques aigus : le point de vue d'un neurochirurgien. Cet article entend revenir sur notre expérience d'utilisation des embolectomies aiguës de l'artère cérébrale moyenne (ACM) dans les années 1990. À l'époque, une telle technique était désapprouvée par les experts de l'AVC et ne pouvait se comparer au traitement nouvellement introduit et éprouvé de l'AVC ischémique aigu au moyen de l'activateur tissulaire recombinant du plasminogène par voie intraveineuse (l'altéplase). Au cours des dernières décennies, la revascularisation cérébrale d'AVC ischémiques aigus a connu des avancées spectaculaires, le principal changement de paradigme étant la thrombectomie endovasculaire (TEV). La thrombectomie mécanique est ainsi passée de la salle d'opération, là où nous la pratiquions, à la salle d'angiographie interventionnelle équipée de technologies d'aspiration et de récupération des caillots toujours plus performantes.

Keywords: Acute ischemic stroke; mechanical thrombectomy; microembolectomy; thrombolysis

(Received 26 May 2024; date of acceptance 17 June 2024; First Published online 5 November 2024)

In the 1990s, the “hyperdense middle cerebral artery (MCA) sign” on an unenhanced CT scan was recognized as highly specific for an embolic occlusion of the MCA and quite easily seen on an axial cut through that artery's horizontal segment in the Sylvian fissure.^{1,2} Although a CT sign with low overall sensitivity for detection of an occluded MCA, it was the only available marker of large vessel occlusion before the introduction of computed tomographic angiography. When found in a patient with sudden contralateral hemiplegia, an urgent neurology consult was sought and, in some cases, one from neurosurgery as well. My personal interest in micro neurosurgery and stroke (I was the principal surgeon in our city for the North American Symptomatic Carotid Endarterectomy Trial)³ was being increasingly recognized in my hospital.

Given the generally very poor prognosis of patients presenting with proximal MCA occlusion (M1 segment) and hemiplegia (i.e., death or dependency), emergency MCA microsurgical embolectomy was an option, provided that an established MCA territory infarct was not evident on CT. Between 1990 and 1999, we performed 10 MCA embolectomies: 3 based on the hyperdense MCA sign followed by catheter angiography to confirm and the

next 7 based on the MCA hyperdense sign alone to save valuable time. The mean time from stroke onset to revascularization in our small series was 4 hours. Postoperative patency was proven in 9 of the 10, with the remaining patient having died from a hemorrhagic transformation shortly after surgery. Follow-up CT imaging showed mostly small deep perforator zone infarctions in eight patients and MCA branch infarcts in four, but there were no whole MCA territory infarctions. At 3–6 months post-stroke, all nine surviving patients had a minor to moderate stroke deficit (modified Rankin score 3 or better). We considered these results in this small case series quite good compared to what we *assumed* was the natural history with medical management alone.

Intracranial embolectomy was rarely performed but certainly not a new operation in the 1990s. The first MCA embolectomy was reported in 1957 by Welch,⁴ followed by another report by Jacobson et al. in 1962⁵ and a subsequent report in 1963 by Chou.⁶ An intracranial internal carotid saddle embolus extending into both the MCA and anterior cerebral arteries was microsurgically removed in 1963 by the neurosurgeon Lougheed, who then reported the case in 1965 along with neurologists Gunton and

Corresponding author: Jay Max Findlay; Email: jmaxfindlay@gmail.com

Cite this article: Findlay JM. (2025) A Look Back on the History of Cerebral Revascularization for Acute Ischemic Stroke: A Neurosurgeon's Perspective. *The Canadian Journal of Neurological Sciences* 52: 347–350, <https://doi.org/10.1017/cjn.2024.292>

© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.




Figure 1. Photographs of a left middle cerebral artery embolectomy micro-embolotomy. Panel “d” shows thrombus herniating from an arteriotomy in the inferior M2 division, and panel “e” shows the arteriotomy closure with three interrupted 9-0 Prolene sutures.




Figure 2. A diagram explaining the size and extent of the deep “perforator” infarcts uniformly seen in our middle cerebral artery embolectomy case series.

Barnett at the Toronto General Hospital.⁷ In 1985, Meyer and colleagues at the Mayo Clinic reviewed 64 reported cases of intracranial embolectomies and presented their own series of 20 who underwent embolectomy for acute occlusion of the MCA between 1970 and 1983.⁸ Seventy percent of their patients had a fair to good outcome, two died, and collateral flow, as judged from the preoperative angiogram, was the best predictor of a good prognosis. Despite these positive reports (surgical “tour de force” publications, not unlike our own), intracranial embolectomy was almost never done. Patients who could have been considered were not referred to surgeons with the appropriate skill set (and there were not many) within a time frame where revascularization might be successful in averting a major stroke.

The local and then national opinion of presentations of our approach and early results with MCA embolectomies⁹ (Figures 1 and 2) was critical, with the operation considered reckless and unproven. Anticipating a poor reception, at the beginning of my presentation at the Canadian Congress in 1997, I warned the audience of mostly neurologists (including several very eminent Canadian stroke neurologists) that “I am going to try to *not* leave time for questions or comments.” However, the moderator allowed the discussion to proceed over time, providing ample time for (mostly) polite condemnation to ensue.

To be fair, 1997 was a time when a “proven” reperfusion treatment had just arrived on the stroke scene, namely, the thrombolytic agent recombinant human tissue plasminogen activator (rt-PA or simply t-PA, aka “alteplase”), administered

intravenously (10% of a 0.9 mg/kg dose given as a bolus and the remainder infused over the following hour) within 3 hours of stroke onset, provided the patient’s CT scan was relatively normal.¹⁰ The NINDS trials showed that compared to patients given placebo, patients treated with t-PA were at least 30% more likely to have no or minimal disability at 3 months. Intravenous alteplase given in the emergency department versus an emergency craniotomy for an acute ischemic stroke was no contest, and acute stroke referrals to our neurosurgical service soon ended. The NINDS t-PA trial led to a new standard of care, and acute stroke protocols were established by emerging “stroke services,” generally led by neurologists.

Interventional neuroradiology was becoming established as a subspecialty in the 1990s, and there was a growing interest in intraarterial thrombolysis for acute ischemic stroke. Large vessel occlusions were the target, where the likelihood of successful recanalization with intravenously administered alteplase was increasingly recognized as being less likely than in more distal occlusions.¹¹ The “Prolyse in Acute Cerebral Thromboembolism Trials (PROACT)” I and II were published in 1998 and 1999, respectively.^{12,13} In brief, intraarterial recombinant pro-urokinase (“prolyse” another thrombolytic agent), given within 6 hours of stroke onset and administered through a microcatheter directly proximal and into emboli, resulted in a higher rate of recanalization than placebo and improved outcome. Prolyse was never approved by the FDA for acute stroke, which cited the need for a larger confirmatory trial that was never performed. When the FDA revoked prolyse’s GMP (Good Manufacturing Process) certificate,

it became unavailable for use, and for a time, alteplase was used instead but also recognized as being far too slow. Faster, more effective endovascular revascularization techniques were needed and indeed were in development.

In 2000, Chopko and colleagues published the first reported case of a transfemoral endovascular “mechanical” clot retrieval of an MCA embolus using a “goose-neck snare” after an unsuccessful attempt at intraarterial thrombolysis.¹⁴ The 38-year-old patient made a rapid recovery. The era of trans-arterial mechanical thrombectomy began with the development of the corkscrew-like “MERCİ” (Mechanical Embolus Removal in Cerebral Ischemia) clot retriever device, designed at the University of California in 2001 and the first device approved in the USA to remove intracranial emboli in 2004.¹⁵ The feasibility and efficacy of this first-generation clot retriever were soon established in a prospective nonrandomized multicenter study.¹⁶ About one-half of the 141 patients in whom the device was deployed were recanalized, and roughly one-half of those patients had a good outcome, a highly significant difference from the patients in whom recanalization was not achieved.

The off-label use of arterial stents as clot retrievers (i.e., stenting the clot and then pulling out the stent along with the clot) were soon recognized to be more effective and safer than the MERCİ device, which opened the stroke field to devices designed specifically for neuro-interventional use. Randomized trials comparing mechanical thrombectomy to medical care-alone treatment in eligible patients quickly confirmed the efficacy of this approach^{17–21} (the Berkhemer et al. MRCLEAN study especially persuasive¹⁷), and in 2015, the American Heart and Stroke Association published guidelines stating that mechanical thrombectomy had Class 1, Level A evidence for efficacy and should be provided to patients at centers with endovascular capability.²² A paradigm shift in stroke care had taken place.

At the same time, developments continued in intravenous thrombolysis. Multiple trials studying alteplase for acute ischemic stroke confirmed its efficacy up to 4.5 hours following stroke onset and up to 9 hours from stroke onset, as well as patients who woke with symptoms, in patients selected based on advanced multimodal CT or MRI imaging.²³ More recently a newer and improved thrombolytic agent, tenecteplase (or “TNK”) has joined and is now supplanting alteplase in stroke treatment.²⁴ Because of its longer half-life (22 vs. 4 minutes for alteplase), it can be administered as a single bolus rather than the less practical bolus and hour-long infusion for alteplase. Compared to alteplase, it also has a much higher affinity for fibrin along with a lower binding affinity for plasminogen activator inhibitor, which at least in theory makes it a more effective thrombolytic agent with a reduced risk of bleeding.²⁵ Clinical trials have demonstrated that tenecteplase is non-inferior to alteplase,²⁶ but ease of administration has led to increasing use in many jurisdictions.²⁴

The current state of the art for appropriately screened and selected acute ischemic stroke patients is constantly changing, but currently, it involves urgent revascularization, starting with intravenous TNK followed by endovascular thrombectomy, with eligibility based on clinical presentation, duration of symptoms and CT imaging.²⁴ Mechanical thrombectomy has moved from the operating suite, where I performed it, to the interventional angiography suite armed with ever-improving clot aspiration techniques and technology, making it a growing and lucrative industry now.

The human, hospital and neurovascular equipment resources required for “24/7” stroke service have exploded and are difficult to

sustain.²⁷ The limited availability of stroke experts and interventionalists, as well as finite hospital care capabilities, along with the narrow window of opportunity for intervention, has resulted in significant inequities in acute stroke care across our country and indeed around the world. The greatest source of inequity is geographic, particularly in countries such as Canada, where patients in rural and remote areas are disadvantaged by virtue of the time taken to transfer to metropolitan centers with these services.

I began this review by recalling our much-maligned foray into acute MCA embolectomy operations in the 1990s before the dramatic developments in medical and endovascular stroke management summarized above. Ours was a mechanical embolectomy from the *outside*, which was impractical, but as it turned out, and despite protests from my senior colleagues at the time, *on the right track!* And it’s interesting that case reports of this obscure operation still occasionally appear in the literature, in some cases because endovascular treatment is unavailable²⁸ or when thrombolysis either failed²⁹ or was impossible due to a proximal carotid occlusion.³⁰

All I can tell young neurosurgeons who might someday, under some unusual circumstance, consider doing an intracranial embolectomy is to first make sure you have the right instruments (such as an extracranial to intracranial or “EC-IC” bypass kit) and sutures (9-0 Prolene) available. But most importantly, you *must* have a temporary aneurysm clip poised over the artery proximal to the arteriotomy as you tease that embolus out with micro instruments and gentle suction. Slowly at first, but then bursting out like a cork from a champagne bottle with a blast of arterial blood behind it. It is a very gratifying surgical experience once the tiny arteriotomy is repaired, but as in all vascular operations, proximal control is essential.

Funding statement. None.

Competing interests. None.

References

1. Bastianello S, Perallini A, Colonnese C, et al. Hyperdense middle cerebral artery CT sign. *Neuroradiology*. 1991;33:207–11.
2. von Kummer R, Meyding-Lamade U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. *Am J Neuroradiol*. 1994;15:5–15.
3. The North American Symptomatic Carotid Endarterectomy Trial Collaborators. The north American symptomatic carotid endarterectomy trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. *N Engl J Med*. 1991;325:445–53.
4. Welch K. Excision of occlusive lesions of the middle cerebral artery. *J Neurosurg*. 1956;13:73–80.
5. Jacobson II JH, Wallman LJ, Schumacher GA, Flanagan M, Suarez EL, Donaghy RMP. Microsurgery as an aid to middle cerebral artery endarterectomy. *J Neurosurg*. 1962;19:108–15.
6. Chou SN. Embolectomy of middle cerebral artery. Report of a case. *J Neurosurg*. 1963;20:161–3.
7. Loughheed WM, Gunton RW, Barnett HJM. Embolectomy of internal carotid, middle and anterior cerebral arteries. Report of a case. *J Neurosurg*. 1965;22:607–9.
8. Meyer FB, Piepgras DG, Sundt TM Jr, Yanagihara T. Emergency embolectomy for acute occlusion of the middle cerebral artery. *J Neurosurg*. 1985;62:639–47.
9. Findlay JM. Microsurgical middle cerebral artery embolectomy revisited. *Can J Neuro Sci*. 1997;supp 24:13.
10. NINDS tPA Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med*. 1995;333:1581–7.

11. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. *Am J Neurorad.* 1996;17:79–85.
12. Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. *Stroke.* 1998;29:4–11.
13. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke-the PROACT II study: a randomized controlled trial. *JAMA.* 1999;282:2003–11.
14. Chopko BW, Kerber C, Wong W, Georgy B. Transcatheter snare removal of acute middle cerebral thromboembolism: technical case report. *Neurosurgery.* 2000;46:1529–31.
15. Smith WS, Furlan A. Brief history of endovascular acute ischemic stroke treatment. *Stroke.* 2016;47:e23–e26.
16. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. *Stroke.* 2005;36:1432–8.
17. Berkhemer O.A., Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015;372:11–20.
18. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel stroke: a meta-analysis of individual patient data from five randomized trials. *Lancet.* 2016;387:1723–831.
19. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015;372:2285–95.
20. Campbell BCV, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Eng J Med.* 2015;372:1009–18.
21. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Eng J Med.* 2015;372: 2296–306.
22. Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment. *Stroke.* 2015;46:3020–35.
23. Campbell BCV, Meretoja A, Donnan GA, Davis SM. Twenty-year history of the evolution of stroke thrombolysis with intravenous alteplase to reduce long-term disability. *Stroke.* 2015;46:2341–6.
24. Heran M, Lindsay P, Gubitz G, et al. Canadian stroke best practice recommendations: acute stroke management, 7th edition practice guidelines update, 2022. *Can J Neurol Sci.* 2024;51:1–31.
25. Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. *N Engl J Med.* 2018;378:1573–82.
26. Shen Z, Bao N, Tang M, et al. Tenecteplase vs. alteplase for intravenous thrombolytic therapy of acute ischemic stroke: a systematic review and meta-analysis. *Neurol Ther.* 2023;12:1553–72.
27. Hu SX, Virani K, Shankar JJS, Christian CA, et al. Case-control study of endovascular thrombectomy in a Canadian stroke center. *Can J Neurol Sci.* 2020;47:44–9.
28. Hino A, Oka H, Hashimoto Y, et al. Direct microsurgical embolectomy for acute occlusion of the internal carotid artery and middle cerebral artery. *World Neurosurg.* 2016;88:243–51.
29. Katsuno M, Kawasaki K, Izumi N, Hashimoto M. Surgical embolectomy for middle cerebral artery occlusion after thrombolytic therapy: a report of two cases. *Surg Neurol Int.* 2014;5:93–8.
30. Yanagawa T, Harada Y, Kiyomoto M, Yamashita K, Hatayama T. Emergency embolectomy for acute middle cerebral artery occlusion with chronic common carotid artery occlusion. *Radiol Case Rep.* 2020;15:375–8.